Brazergoline

Brazergoline
Clinical data
Other names	Luvion; 2-Bromo-6-methylergoline-8β-methanol hexahydro-1H-azepine-1-carboxylate
Drug class	Sympatholytic; Antihypertensive; Vasodilator
ATC code	None;
Identifiers
	IUPAC name [(6aR,9R,10aR)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]methyl azepane-1-carboxylate;
CAS Number	60019-20-7;
PubChem CID	10095768;
DrugBank	DB20548;
ChemSpider	8271303;
UNII	C9734VZR4O;
ChEMBL	ChEMBL2106110;
CompTox Dashboard (EPA)	DTXSID401024239 ;
Chemical and physical data
Formula	C23H30BrN3O2
Molar mass	460.416 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C[C@@H](C[C@H]2[C@H]1CC3=C(NC4=CC=CC2=C34)Br)COC(=O)N5CCCCCC5;
	InChI InChI=1S/C23H30BrN3O2/c1-26-13-15(14-29-23(28)27-9-4-2-3-5-10-27)11-17-16-7-6-8-19-21(16)18(12-20(17)26)22(24)25-19/h6-8,15,17,20,25H,2-5,9-14H2,1H3/t15-,17-,20-/m1/s1; Key:MMPCMJGFURZYOY-WRWLIDTKSA-N;

Brazergoline (INNTooltip International Nonproprietary Name; synonym Luvion) is a drug described as a sympatholytic, antihypertensive, and vasodilator of the ergoline family which was never marketed.^[1]^[2]^[3]^[4] It was reportedly investigated as a component of a condom with penile erection-promoting effects and as a potential treatment for female sexual dysfunction.^[4] The drug was first described in the literature by 1976.^[1]